Ligelizumab

Ligelizumab (QGE031) (INN) is a humanized monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. It binds to IGHE an acts as an immunomodulator. Ligelizumab (QGE031) (INN) is a humanized monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. It binds to IGHE an acts as an immunomodulator. This drug was developed by Novartis Pharma AG. As of 2018, ligelizumab is undergoing Phase III trials.